SEC Form 4 · accession 0001144204-17-049725
Marker Therapeutics, Inc. · MRKR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Glynn Wilson
Director
Period of report
Sep 22, 2017
Accepted (ET)
Sep 26, 2017 · 4:05 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001094038
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 22, 2017 | A | 100,000 | $3.18 | A | 185,567 | D | |
| Common StockF2 | Sep 22, 2017 | F | 27,350 | $3.18 | D | 158,217 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares of fully vested restricted stock issued under the Company's 2014 Omnibus Stock Ownership Plan in connection with the execution of amendment to employment agreement reflecting change in status from President and Chief Executive Officer to Strategic Advisor.
- F2Represents withholding of shares of common stock to satisfy tax withholding obligations in connection with the issuance of the restricted stock award.